better for weight loss semaglutide or tirzepatide vs. Semaglutide: Which Medication Is Right You? Tirzepatide vs. Semaglutide: Which is

In the double-blind, placebo-controlled ATTAIN-1 trial, continuous use of the highest dose of Foundayo led to an average weight loss of 12.4% (27.3 pounds) after 72 weeks, compared with 0.9% (2.2 pounds) with placebo

Weight loss outcomes similarly show a gradient of effectiveness

Similar content being viewed by others 1 Introduction Semaglutide (US brand name Ozempic or Wegovy), a Glucagon-like peptide-1 receptor (GLP-1R) agonist containing the active ingredient semaglutide, is approved by the Food and Drug Administration for its potential therapeutic role in obesity and diabetes mellitus (DM) similar to other agonists within the GLP-1R family such as liraglutide

doi: 10.1155/ije/2876156

doi: 10.1186/2049-6958-6-1-28 130 PorebskiGWozniakMCzarnobilskaE